NTRK1 and cancer: MET, the receptor tyrosine kinase (RTK) for scatter factor/hepatocyte growth factor, is involved in acquisition and maintenance of critical oncogenic and invasive features in several types of human cancer and represents a promising molecular therapeutic target.